Report cover image

Radiotheranostics Market Growth, Size, Trends Analysis - By Radioisotope, By Approach, By Application - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Publisher SPER Market Research Pvt. Ltd.
Published May 14, 2025
Length 222 Pages
SKU # SPER20186973

Description

Radiotheranostics Market Introduction and Overview

According to SPER market research, ‘Global Radiotheranostics Market Size- By Radioisotope, By Approach, By Application – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Radiotheranostics Market is predicted to reach 35.22 billion by 2034 with a CAGR of 13.74%.

Radiotheranostics is a new area in medicine that merges diagnosis and treatment using radiopharmaceuticals. It uses radiotracers, which are molecules with radioactive isotopes, to diagnose and treat diseases at the same time. Techniques like positron emission tomography (PET) or single-photon emission computed tomography (SPECT) are used to identify specific targets in the body, offering precise and personalized diagnosis by detailing the disease’s location and extent. The treatment entails providing radiation therapy to the illness site.

Restraints:

The high cost of radiopharmaceuticals and radiotheranostics treatments can cause problems for patients and healthcare professionals alike. The cost-effectiveness and affordability of these technologies need to be addressed in order to ensure further adoption and market expansion.

Scope of the report:

Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered By Radioisotope, By Approach, By Application

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

Novartis AG, Bayer AG, Progenics Pharmaceuticals, Inc. (Lantheus), Telix Pharmaceuticals Limited, ITM Radiopharma, Life Molecular Imaging, RadioMedix, IsoTherapeutics Group, LLC, Q BioMed Inc, Nordic Nanovector ASA.

Global Radiotheranostics Market Segmentation:

By Radioisotope:

Based on the Radioisotope, Global Radiotheranostics Market is segmented as; Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90.

By Approach:

Based on the Approach, Global Radiotheranostics Market is segmented as; Targeted Therapeutic, Targeted Diagnostic.

By Application:

Based on the Application, Global Radiotheranostics Market is segmented as; Oncology, Non-oncology.

By Region:

This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Table of Contents

222 Pages
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Radiotheranostics Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Radiotheranostics Market
7. Global Radiotheranostics Market, By Radioisotope (USD Million) 2021-2034
7.1. Iodine-131
7.2. Iodine-123
7.3. Gallium-68
7.4. Lutetium-177
7.5. 18 F with Y-90
7.6. Others
8. Global Radiotheranostics Market, By Approach (USD Million) 2021-2034
8.1. Targeted Therapeutic
8.2. Targeted Diagnostic
9. Global Radiotheranostics Market, By Application (USD Million) 2021-2034
9.1. Oncology
9.1.1. Thyroid Cancer
9.1.2. Neuroendocrine Tumor
9.1.3. Hepatocellular Carcinoma
9.1.4. Prostate Cancer
9.1.5. Others
9.2. Non-oncology
9.2.1. Neurological Disorders
9.2.2. Arthritis
9.2.3. Others
10. Global Radiotheranostics Market, (USD Million) 2021-2034
10.1. Global Radiotheranostics Market Size and Market Share
11. Global Radiotheranostics Market, By Region, (USD Million) 2021-2034
11.1. Asia-Pacific
11.1.1. Australia
11.1.2. China
11.1.3. India
11.1.4. Japan
11.1.5. South Korea
11.1.6. Rest of Asia-Pacific
11.2. Europe
11.2.1. France
11.2.2. Germany
11.2.3. Italy
11.2.4. Spain
11.2.5. United Kingdom
11.2.6. Rest of Europe
11.3. Middle East and Africa
11.3.1. Kingdom of Saudi Arabia
11.3.2. United Arab Emirates
11.3.3. Qatar
11.3.4. South Africa
11.3.5. Egypt
11.3.6. Morocco
11.3.7. Nigeria
11.3.8. Rest of Middle-East and Africa
11.4. North America
11.4.1. Canada
11.4.2. Mexico
11.4.3. United States
11.5. Latin America
11.5.1. Argentina
11.5.2. Brazil
11.5.3. Rest of Latin America
12. Company Profile
12.1. Novartis AG
12.1.1. Company details
12.1.2. Financial outlook
12.1.3. Product summary
12.1.4. Recent developments
12.2. Bayer AG
12.2.1. Company details
12.2.2. Financial outlook
12.2.3. Product summary
12.2.4. Recent developments
12.3. Progenics Pharmaceuticals, Inc.(Lantheus)
12.3.1. Company details
12.3.2. Financial outlook
12.3.3. Product summary
12.3.4. Recent developments
12.4. Telix Pharmaceuticals Limited
12.4.1. Company details
12.4.2. Financial outlook
12.4.3. Product summary
12.4.4. Recent developments
12.5. ITM Radiopharma
12.5.1. Company details
12.5.2. Financial outlook
12.5.3. Product summary
12.5.4. Recent developments
12.6. Life Molecular Imaging
12.6.1. Company details
12.6.2. Financial outlook
12.6.3. Product summary
12.6.4. Recent developments
12.7. RadioMedix
12.7.1. Company details
12.7.2. Financial outlook
12.7.3. Product summary
12.7.4. Recent developments
12.8. IsoTherapeutics Group, LLC
12.8.1. Company details
12.8.2. Financial outlook
12.8.3. Product summary
12.8.4. Recent developments
12.9. Q BioMed Inc
12.9.1. Company details
12.9.2. Financial outlook
12.9.3. Product summary
12.9.4. Recent developments
12.10. Nordic Nanovector ASA
12.10.1. Company details
12.10.2. Financial outlook
12.10.3. Product summary
12.10.4. Recent developments
12.11. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us